Aridis' ar-301 monoclonal antibody is among the first biologics to receive fda's qualified infectious diseases product (qidp) designation

Los gatos, calif., july 12, 2023 (globe newswire) -- aridis pharmaceuticals, inc. (nasdaq: ards), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced that the u.s. food and drug administration (fda) has granted qualified infectious disease product (qidp) designation under the generating antibiotic incentives now (gain) act for ar-301, a fully human igg1 monoclonal antibody (mab) currently in phase 3 clinical development as an adjunctive therapy for pneumonia caused by gram-positive staphylococcus aureus in critically ill hospitalized patients.
ARDS Ratings Summary
ARDS Quant Ranking